Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003235 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed | completed | Phase 3 | 294 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03728556 | A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer | completed | Phase 3 | 381 | CStone PharmaceuticalsINDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02766335 | Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | completed | Phase 2 / Phase 3 | 116 | SWOG Cancer Research NetworkNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05496166 | The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 348 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05157776 | A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations | unknown | Phase 3 | 72 | Tongji UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03523468 | Curative Effect and Quality of Life Between Uniportal and Open Sleeve Lobectomy for Central Type Lung Cancer | unknown | Phase 3 | 200 | Lei JiangOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05001724 | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent | terminated | Phase 2 / Phase 3 | 16 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05767892 | YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | not yet recruiting | Phase 3 | 350 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT01257139 | Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments(ESOGIA) | completed | Phase 3 | 490 | Rennes University HospitalOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03991403 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | unknown | Phase 3 | 228 | Samsung Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05104281 | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 60 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study(STAD-1) | unknown | Phase 3 | 160 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01405586 | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer(MILES-3) | unknown | Phase 3 | 299 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01656551 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer(MILES-4) | unknown | Phase 3 | 232 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT00385606 | Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC | completed | Phase 2 / Phase 3 | 400 | National Cancer Institute, NaplesOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04241315 | ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting(Elucidate) | completed | Phase 3 | 112 | On Target Laboratories, LLCINDUSTRY | 1 | Mar 23, 2023 | clinicaltrials |
| NCT01763671 | Paclitaxel-bevacizumab in Advanced Lung Cancer(Ultimate) | completed | Phase 3 | 166 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT01850303 | Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer(MODEL) | completed | Phase 3 | 632 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | completed | Phase 3 | 541 | Bristol-Myers SquibbINDUSTRY | 26 | Mar 2, 2023 | clinicaltrials |
| NCT03351361 | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients(eNERGY) | completed | Phase 3 | 217 | Rennes University HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03150875 | A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC | completed | Phase 3 | 290 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02713867 | A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384) | completed | Phase 3 | 363 | Bristol-Myers SquibbINDUSTRY | 8 | Feb 14, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05725343 | A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer(CANAL) | terminated | Phase 3 | 350 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT03856411 | A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC | completed | Phase 3 | 465 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03196986 | mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 517 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03849768 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | unknown | Phase 3 | 429 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03682224 | Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients(BEMP) | completed | Phase 3 | 57 | Southern Illinois UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02813785 | A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy(IMpower210) | completed | Phase 3 | 565 | Hoffmann-La RocheINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT02538666 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy(CheckMate 451) | completed | Phase 3 | 907 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 5, 2023 | clinicaltrials |
| NCT05661240 | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment | unknown | Phase 2 / Phase 3 | 348 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05648071 | First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial(SPBPDC) | unknown | Phase 3 | 60 | Qianfoshan HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT00017407 | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer | completed | Phase 3 | — | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT05042375 | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 450 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT03515629 | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | terminated | Phase 3 | 5 | Regeneron PharmaceuticalsINDUSTRY | 3 | Nov 16, 2022 | clinicaltrials |
| NCT05605613 | PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial | unknown | Phase 2 / Phase 3 | 150 | Xuhua DuanOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT02066636 | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen(CheckMate153) | completed | Phase 3 | 1,428 | Bristol-Myers SquibbINDUSTRY | 2 | Oct 27, 2022 | clinicaltrials |
| NCT03066778 | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Oct 3, 2022 | clinicaltrials |
| NCT01968941 | Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients(LUSTRE) | completed | Phase 3 | 324 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04942275 | Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy(PEGASUS) | unknown | Phase 2 / Phase 3 | 60 | University Hospital, BrestOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT00377156 | Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases | completed | Phase 3 | 213 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03922997 | A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 101 | Hoffmann-La RocheINDUSTRY | 1 | Sep 9, 2022 | clinicaltrials |
| NCT02856581 | Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes | terminated | Phase 3 | 23 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 27, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Jun 15, 2023source: clinicaltrials